Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Takeda Pharmaceutical Co. Ltd ADR (TAK)

Takeda Pharmaceutical Co. Ltd ADR (TAK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,492,940
  • Shares Outstanding, K 3,164,505
  • Annual Sales, $ 31,764 M
  • Annual Income, $ 2,048 M
  • 60-Month Beta 0.73
  • Price/Sales 1.38
  • Price/Cash Flow 3.94
  • Price/Book 0.87
Trade TAK with:

Options Overview Details

View History
  • Implied Volatility 22.72% ( -0.54%)
  • Historical Volatility 20.15%
  • IV Percentile 23%
  • IV Rank 20.62%
  • IV High 36.20% on 12/31/21
  • IV Low 19.21% on 08/02/21
  • Put/Call Vol Ratio 0.50
  • Today's Volume 3
  • Volume Avg (30-Day) 111
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 14,589
  • Open Int (30-Day) 14,282

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.51
  • Growth Rate Est. (year over year) +195,782.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.05 +6.67%
on 06/17/22
14.48 -3.83%
on 05/31/22
-0.85 (-5.72%)
since 05/27/22
3-Month
13.05 +6.67%
on 06/17/22
15.18 -8.27%
on 04/08/22
-0.60 (-4.10%)
since 03/28/22
52-Week
13.05 +6.67%
on 06/17/22
17.31 -19.56%
on 09/21/21
-2.96 (-17.55%)
since 06/28/21

Most Recent Stories

More News
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

Takeda ( TSE:4502/NYSE:TAK ) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that results from a Phase 2 clinical study (AROAAT-2002) of investigational fazirsiran (TAK-999/ARO-AAT)...

TAK : 13.91 (-1.07%)
ARWR : 33.24 (-1.42%)
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

Takeda ( TSE:4502/NYSE:TAK ) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that results from a Phase 2 clinical study (AROAAT-2002) of investigational fazirsiran (TAK-999/ARO-AAT)...

TAK : 13.91 (-1.07%)
ARWR : 33.24 (-1.42%)
Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts

Takeda ( TSE:4502/NYSE:TAK ) today announced that it has signed a 15-year lease with BioMed Realty for approximately 600,000 square feet of research and development (R&D) and office space to be built...

TAK : 13.91 (-1.07%)
As Health Problems Mount Patients Welcome New Treatments

Palm Beach, FL – June 14, 2022 – FinancialNewsMedia.com News Commentary – There are several serious health problems facing society today. Some, like heart disease, gastrointestinal diseases, cancer,...

CRDL : 1.5500 (-4.91%)
CRDL.TO : 1.95 (-6.70%)
TAK : 13.91 (-1.07%)
ABT : 108.15 (-0.85%)
BMY : 79.02 (-1.20%)
NVO : 109.04 (-3.41%)
Want Loads of Passive Income? Avoid These 3 (Very) Tempting Mistakes

Improving your investing process tends to have high returns.

TAK : 13.91 (-1.07%)
GSK : 43.41 (-0.66%)
IIPR : 114.48 (-2.42%)
COST : 473.20 (-1.77%)
Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial

Takeda ( TSE:4502/NYSE:TAK ) today announced that its dengue vaccine candidate, TAK-003, prevented 84% of hospitalized dengue cases and 61% of symptomatic dengue cases, with no important safety risks...

TAK : 13.91 (-1.07%)
Takeda Canada applauds Quebec's new Rare Disease Policy

/CNW/ - Takeda Canada Inc. ("Takeda Canada"), a values-based, R&D-driven biopharmaceutical leader, committed to discovering and delivering life-transforming...

TAK : 13.91 (-1.07%)
Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it will present data at two upcoming scientific congresses this spring: the 58 th Annual Meeting of...

TAK : 13.91 (-1.07%)
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Takeda ( TSE:4502/NYSE:TAK ) announced to transfer the marketing authorization in...

TAK : 13.91 (-1.07%)
MRNA : 144.39 (-0.67%)
Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna

Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for SpikevaxTM from August 1, 2022...

MRNA : 144.39 (-0.67%)
TAK : 13.91 (-1.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide...

See More

Key Turning Points

3rd Resistance Point 14.33
2nd Resistance Point 14.23
1st Resistance Point 14.14
Last Price 13.91
1st Support Level 13.95
2nd Support Level 13.85
3rd Support Level 13.76

See More

52-Week High 17.31
Fibonacci 61.8% 15.68
Fibonacci 50% 15.18
Fibonacci 38.2% 14.68
Last Price 13.91
52-Week Low 13.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar